Drug Trial Radar · NCT04833894
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Actual
Start
Oct 26, 2021
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Apr 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG. Trial details include: * The maximum trial duration for each individual participant will be approximately 28 weeks * The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment response-confirmatory part (Part B)
Conditions
- Generalized Myasthenia Gravis
Interventions
Efgartigimod IVBiological
Intravenous infusion of Efgartigimod
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Clearance (CL)Time frame: up to 26 weeks
- Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Volume of Distribution (Vd)Time frame: up to 26 weeks
- Total Immunoglobulin G (IgG) levels as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysisTime frame: up to 26 weeks
- Anti-acetylcholine receptors antibodies (AChR-Ab) as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysisTime frame: up to 26 weeks
Locations
25 sites in 12 countries. Site status is shown where the registry gives one.
Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital
Chicago, Illinois
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
University of Virginia (UVA) Health - Developmental Pediatrics Clinic
Charlottesville, Virginia
Medizinische Universitat Wien
Vienna, Austria
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium
Alberta Childrens Hospital
Calgary, Canada
British Columbia Children's Hospital
Vancouver, Canada
AP-HM - Hopital de la Timone
Marseille, France
Assistance Publique Hopitaux de Paris (AP-HP) - Hopital Necker-Enfants Malades
Paris, France
Vian - M. Iashvili Children's Central Hospital
Tbilisi, Georgia
Tbilisi State Medical University - Givi Zhvania Pediatric Academic Clinic
Tbilisi, Georgia
Charite Universitaetsmedizin Berlin - Campus Virchow-Klinikum - Sozialpadiatrisches Zentrum
Berlin, Germany
Universitätsklinikum Essen
Essen, Germany
Azienda Ospedaliera Universitaria Policlinico Consorziale Di Bari
Bari, Italy
Azienda Ospedaliero Universitaria A. Meyer
Florence, Italy
Ospedale Giannina Gaslini
Genova, Italy
Leids Universitair Medisch Centrum
Leiden, Netherlands
Centralny Szpital Kliniczny - Uniwersyteckie Centrum Kliniczne WUM
Warsaw, Poland
Uniwersyteckie Centrum Kliniczne
Gdansk, Woj. Pomorskie, Poland
Wielospecjalistyczna Poradnia Lekarska Synapsis
Katowice, Woj. Slaskie, Poland
Hospital Sant Joan de Deu
Esplugues de Llobregat, Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain
Great Ormand Street Hospital for Children NHS Foundation Trust - Great Ormond Street Hospital
London, United Kingdom
Manchester University NHS Foundation Trust - Royal Manchester Children's Hospital
Manchester, United Kingdom
Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital Children's Hospital
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.